Evidence map›Paper›PMID 33815382›Full record

ArticleFrontiers in immunology2021

Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics.

Holger Heine, Florian Adanitsch, Tina Tinkara Peternelj, Mira Haegman, Christoph Kasper, Simon Ittig, Rudi Beyaert, Roman Jerala, Alla Zamyatina

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Approaches to stereoselective 1,1'-glycosylation.Beilstein journal of organic chemistry · 2025
    Review
  6. Article
  7. Serine-/Cysteine-Based spJournal of medicinal chemistry · 2023
    Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Holger HeineResearch Group Innate Immunity, Research Center Borstel - Leibniz Lung Center, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany.
Florian AdanitschDepartment of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria.
Tina Tinkara PeterneljDepartment of Biotechnology, National Institute of Chemistry, University of Ljubljana, Ljubljana, Slovenia.
Mira HaegmanUnit of Molecular Signal Transduction in Inflammation, Department of Biomedical Molecular Biology, Ghent University, Center for Inflammation Research, VIB, Ghent, Belgium.
Christoph KasperBiozentrum University of Basel, Basel, Switzerland.
Simon IttigBiozentrum University of Basel, Basel, Switzerland.
Rudi BeyaertUnit of Molecular Signal Transduction in Inflammation, Department of Biomedical Molecular Biology, Ghent University, Center for Inflammation Research, VIB, Ghent, Belgium.
Roman JeralaDepartment of Biotechnology, National Institute of Chemistry, University of Ljubljana, Ljubljana, Slovenia.
Alla ZamyatinaDepartment of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria.
BOKU University · ATUniversity of Basel · CHVIB-UGent Center for Inflammation Research · BENational Institute of Chemistry · SIResearch Center Borstel - Leibniz Lung Center · DEUniversity of Ljubljana · SI

Funding

Austrian Science Fund FWF P 28915Austrian Science Fund FWF P 32397
6 · The paper itself

Abstract

Pro-inflammatory signaling mediated by Toll-like receptor 4 (TLR4)/myeloid differentiation-2 (MD-2) complex plays a crucial role in the instantaneous protection against infectious challenge and largely contributes to recovery from Gram-negative infection. Activation of TLR4 also boosts the adaptive immunity which is implemented in the development of vaccine adjuvants by application of minimally toxic TLR4 activating ligands. The modulation of pro-inflammatory responses via the TLR4 signaling pathway was found beneficial for management of acute and chronic inflammatory disorders including asthma, allergy, arthritis, Alzheimer disease pathology, sepsis, and cancer. The TLR4/MD-2 complex can recognize the terminal motif of Gram-negative bacterial lipopolysaccharide (LPS)-a glycophospholipid lipid A. Although immense progress in understanding the molecular basis of LPS-induced TLR4-mediated signaling has been achieved, gradual, and predictable TLR4 activation by structurally defined ligands has not yet been attained. We report on controllable modulation of cellular pro-inflammatory responses by application of novel synthetic glycolipids-disaccharide-based lipid A mimetics (DLAMs) having picomolar affinity for TLR4/MD-2. Using crystal structure inspired design we have developed endotoxin mimetics where the inherently flexible β(1 → 6)-linked diglucosamine backbone of lipid A is replaced by a conformationally restricted α,α-(1↔1)-linked disaccharide scaffold. The tertiary structure of the disaccharide skeleton of DLAMs mirrors the 3-dimensional shape of TLR4/MD-2 bound

Indexed as

ImmunomodulationAnimalsBiomimetic MaterialsCytokinesDisaccharidesEscherichia coliHEK293 CellsHumansLeukocytes, MononuclearLipid ALipopolysaccharidesLymphocyte Antigen 96MacrophagesMiceNF-kappa BSignal TransductionCytokinesDisaccharidesLipid ALipopolysaccharidesLymphocyte Antigen 96NF-kappa BToll-Like Receptor 4immune cells activationimmunomodulationinnate immunitylipopolysaccharidepotential adjuvantsynthetic TLR4 agonistTLR4/MD-2 complex activationToll-like Receptor 4

Identifiers

PMID33815382
PMCPMC8012497
OpenAlexW3137837498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.